A Phase II Study of AT7519M, A CDK Inhibitor in Patients with Relapsed and/or Refractory Chronic Lymphocytic Leukemia.

Trial Profile

A Phase II Study of AT7519M, A CDK Inhibitor in Patients with Relapsed and/or Refractory Chronic Lymphocytic Leukemia.

Completed
Phase of Trial: Phase II

Latest Information Update: 29 Mar 2016

At a glance

  • Drugs AT 7519 (Primary)
  • Indications Chronic lymphocytic leukaemia
  • Focus Therapeutic Use
  • Most Recent Events

    • 15 Feb 2015 Status changed from active, no longer recruiting to completed according to ClinicalTrials.gov record.
    • 07 Feb 2014 Planned End Date changed from 1 Jul 2014 to 1 Dec 2014 according to ClinicalTrials.gov record.
    • 22 Nov 2013 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top